Shili Chen

USPTO Granted Patents = 31 (Patent Applications = 11)

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 6 (Patent Applications = 13)

Average Co-Inventor Count = 7.1

ph-index = 9

Forward Citations = 220(Granted Patents)

Location History:

Cheshire, CT (US) (2005 - 2017)
New Haven, CT (US) (2019)
Newark, DE (US) (2017 - 2024)

Company Filing History:

Melinta Therapeutics, Inc.

patents

6 out of 17

Rib-x Pharmaceuticals, Inc.

patents

4. 1 out of 832,843

Other

patents

Years Active: 2005-2025

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459943 - Crystalline solid forms of a BET inhibitor (2025-11-04),

2. 12428426 - Process and intermediates for preparing a JAK1 inhibitor (2025-09-30),

3. 12071439 - Process and intermediates for preparing a JAK inhibitor (2024-08-27),

4. 12030882 - Crystalline solid forms of a bet inhibitor (2024-07-09),

5. 11905292 - Process and intermediates for preparing a JAK inhibitor (2024-02-20),

6. 11897889 - Process and intermediates for preparing a JAK1 inhibitor (2024-02-13),

7. 11866451 - Salts and crystalline forms of a PD-1/PD-L1 inhibitor (2024-01-09),

8. 11780836 - Process of preparing a PD-1/PD-L1 inhibitor (2023-10-10),

9. 11760756 - Crystalline form of a PD-1/PD-L1 inhibitor (2023-09-19),

10. 11377446 - Crystalline solid forms of a BET inhibitor (2022-07-05),

11. 11091480 - Crystalline solid forms of a BET inhibitor (2021-08-17),

12. 10858372 - Amorphous solid form of a BET protein inhibitor (2020-12-08),

13. 10626114 - Crystalline solid forms of a BET inhibitor (2020-04-21),

14. 10329305 - Amorphous solid form of a BET protein inhibitor (2019-06-25),

15. 10259825 - Antimicrobial compounds and methods of making and using the same (2019-04-16),

Title: Innovations and Contributions of Shili Chen in Pharmaceuticals

Introduction

Shili Chen, based in Cheshire, CT, has made significant contributions to the pharmaceutical industry through his innovative inventions. With a remarkable portfolio of 29 patents, he has focused on developing therapeutic agents that address critical health challenges, particularly in the treatment of cancer and other serious diseases.

Latest Patents

Chen's recent patents showcase his pioneering work in drug development. One of his latest inventions is a process and intermediates for preparing a JAK inhibitor. This invention pertains to methodologies for synthesizing baricitinib, along with its salts and related synthetic intermediate compounds. Additionally, he has worked on crystalline solid forms of a BET inhibitor, which is designed to target BET proteins such as BRD2, BRD3, BRD4, and BRD-t. This compound holds promise in treating diseases, including various types of cancer.

Career Highlights

Throughout his career, Shili Chen has been associated with key organizations that are at the forefront of medical research and development. Notably, he has worked with Incyte Corporation, a company known for its focus on innovative therapeutics, and Melinta Therapeutics, Inc., which finds solutions for serious bacterial infections. His experience in these companies has enhanced his expertise in the development and commercialization of new drug therapies.

Collaborations

In his research and development endeavors, Chen has collaborated with notable colleagues, including Jiacheng Zhou and Rongliang Lou. Their combined expertise has driven advancements in their respective fields and has contributed to the successful development of groundbreaking therapeutic agents.

Conclusion

Shili Chen's extensive portfolio of patents and his contributions to pharmaceutical innovations highlight his role as a significant inventor in the industry. His work, particularly on JAK inhibitors and BET inhibitors, showcases the ongoing pursuit of addressing serious health challenges. With continued collaboration and innovation, Chen is likely to remain a key player in the field of drug development for years to come.

This text is generated by artificial intelligence and may not be accurate.